Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $38.0 million.

  • Northwest Biotherapeutics' Total Non-Current Liabilities rose 1163.34% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.0 million, marking a year-over-year increase of 1163.34%. This contributed to the annual value of $37.4 million for FY2024, which is 2597.25% up from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Total Non-Current Liabilities is $38.0 million, which was up 1163.34% from $32.3 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Total Non-Current Liabilities' 5-year high stood at $38.0 million during Q3 2025, with a 5-year trough of $10.1 million in Q3 2022.
  • In the last 5 years, Northwest Biotherapeutics' Total Non-Current Liabilities had a median value of $22.3 million in 2021 and averaged $24.5 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Total Non-Current Liabilities surged by 39271.48% in 2021, and later plummeted by 6589.76% in 2022.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Total Non-Current Liabilities stood at $30.4 million in 2021, then crashed by 65.9% to $10.4 million in 2022, then surged by 186.81% to $29.7 million in 2023, then increased by 25.97% to $37.4 million in 2024, then increased by 1.38% to $38.0 million in 2025.
  • Its Total Non-Current Liabilities stands at $38.0 million for Q3 2025, versus $32.3 million for Q2 2025 and $29.3 million for Q1 2025.